Start › Niedrobnokomórkowy rak płuca › Wirginia › Charlottesville
Badania kliniczne dla Niedrobnokomórkowy rak płuca w mieście Charlottesville, VA
21 badań dla Niedrobnokomórkowy rak płuca szuka uczestników w ośrodkach w mieście Charlottesville i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekrutacjaFaza 1
- Exelixis Clinical Site #66, Charlottesville
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
RekrutacjaFaza 2
- University of Virginia, Charlottesville
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekrutacjaFaza 3
- UVA Comprehensive Cancer Center, Charlottesville
- UVA Health Fontaine Research Park, Charlottesville
- University of Virginia, Charlottesville
- i 1 więcej
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RekrutacjaFaza 3
- University of Virginia Health System, Charlottesville
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
RekrutacjaFaza 2
- University of Virginia Cancer Center, Charlottesville
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RekrutacjaFaza 2/3
- University of Virginia Health System, Charlottesville
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RekrutacjaFaza 3
- Clinical Study Site, Charlottesville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RekrutacjaFaza 3
- University of Virginia Health System, Charlottesville
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
RekrutacjaFaza 1/2
- University of Virginia Cancer Center, Charlottesville
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RekrutacjaFaza 3
- Research Site, Charlottesville
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RekrutacjaFaza 3
- University of Virginia, Charlottesville
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
RekrutacjaFaza 2
- UVA Comprehensive Cancer Center, Charlottesville
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekrutacjaFaza 2
- University of Virginia Cancer Center, Charlottesville
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RekrutacjaFaza 2
- University of Virginia Cancer Center, Charlottesville
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
RekrutacjaFaza 2
- University of Virginia Health System, Charlottesville
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekrutacjaFaza 2/3
- University of Virginia Cancer Center, Charlottesville
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
RekrutacjaFaza 1/2
- University of Virginia, Charlottesville
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
RekrutacjaFaza 2
- University of Virginia Health System, Charlottesville
GEMINI-NSCLC: NSCLC Biomarker Study
RekrutacjaBadanie obserwacyjne
- University of Virginia, Charlottesville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekrutacjaBadanie obserwacyjne
- Massive Bio SYNERGY-AI site, Charlottesville
A Study of NX-1607 in Adults With Advanced Malignancies
RekrutacjaFaza 1
- University of Virginia, Charlottesville
Badania dla Niedrobnokomórkowy rak płuca w innych miastach
- Houston, TX145 badań
- New York City, NY120 badań
- Arlington, VA104 badań
- Nashville, TN97 badań
- Boston, MA90 badań
- Los Angeles, CA87 badań
- St. Louis, MO73 badań
- Chicago, IL61 badań
- Baltimore, MD60 badań
- San Antonio, TX59 badań
- Columbus, OH56 badań
- Washington, DC55 badań
Inne badania w mieście Charlottesville
- Ostra białaczka szpikowa16 badań
- Rak prostaty15 badań
- Nowotwór przerzutowy13 badań
- Rak endometrium13 badań
- Nowotwory (wszystkie typy)13 badań
- Rak płuc13 badań
- Niewydolność serca11 badań
- Rak jajnika10 badań
- Rak jelita grubego i odbytnicy10 badań
- Cukrzyca typu 19 badań
- Rak piersi9 badań
- Rak trzustki9 badań
Źródło: ClinicalTrials.gov, dane pobrane 5 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.